Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3304 | 1346 | 42.6 | 89% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
630 | 9614 | NOONAN SYNDROME//COSTELLO SYNDROME//PROTEIN TYROSINE PHOSPHATASE |
Classes in level below (level 1) |
ID, lev. below | Publications | Label for level below |
---|---|---|
12860 | 814 | SPARC//OSTEONECTIN//BM 40 |
20372 | 401 | GROWTH DIFFERENTIATION FACTOR 15//GDF 15//NAG 1 |
30905 | 131 | FSTL1//TMEFF2//TSC 36 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SPARC | Author keyword | 167 | 54% | 16% | 213 |
2 | GROWTH DIFFERENTIATION FACTOR 15 | Author keyword | 71 | 77% | 4% | 49 |
3 | GDF 15 | Author keyword | 59 | 64% | 4% | 58 |
4 | OSTEONECTIN | Author keyword | 52 | 45% | 7% | 88 |
5 | BM 40 | Author keyword | 35 | 86% | 1% | 18 |
6 | NAG 1 | Author keyword | 32 | 65% | 2% | 31 |
7 | TESTICAN | Author keyword | 26 | 87% | 1% | 13 |
8 | MACROPHAGE INHIBITORY CYTOKINE 1 | Author keyword | 25 | 77% | 1% | 17 |
9 | HEVIN | Author keyword | 23 | 74% | 1% | 17 |
10 | MIC 1 | Author keyword | 19 | 68% | 1% | 17 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SPARC | 167 | 54% | 16% | 213 | Search SPARC | Search SPARC |
2 | GROWTH DIFFERENTIATION FACTOR 15 | 71 | 77% | 4% | 49 | Search GROWTH+DIFFERENTIATION+FACTOR+15 | Search GROWTH+DIFFERENTIATION+FACTOR+15 |
3 | GDF 15 | 59 | 64% | 4% | 58 | Search GDF+15 | Search GDF+15 |
4 | OSTEONECTIN | 52 | 45% | 7% | 88 | Search OSTEONECTIN | Search OSTEONECTIN |
5 | BM 40 | 35 | 86% | 1% | 18 | Search BM+40 | Search BM+40 |
6 | NAG 1 | 32 | 65% | 2% | 31 | Search NAG+1 | Search NAG+1 |
7 | TESTICAN | 26 | 87% | 1% | 13 | Search TESTICAN | Search TESTICAN |
8 | MACROPHAGE INHIBITORY CYTOKINE 1 | 25 | 77% | 1% | 17 | Search MACROPHAGE+INHIBITORY+CYTOKINE+1 | Search MACROPHAGE+INHIBITORY+CYTOKINE+1 |
9 | HEVIN | 23 | 74% | 1% | 17 | Search HEVIN | Search HEVIN |
10 | MIC 1 | 19 | 68% | 1% | 17 | Search MIC+1 | Search MIC+1 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MIC 1 | 122 | 88% | 4% | 58 |
2 | MACROPHAGE INHIBITORY CYTOKINE 1 | 118 | 65% | 8% | 112 |
3 | BINDING PROTEIN SPARC | 76 | 88% | 3% | 36 |
4 | MATRICELLULAR PROTEIN | 72 | 57% | 6% | 85 |
5 | OSTEONECTIN | 68 | 43% | 9% | 121 |
6 | CYSTEINE SPARC | 68 | 80% | 3% | 43 |
7 | SPARC | 66 | 42% | 9% | 123 |
8 | MATRICELLULAR PROTEIN SPARC | 52 | 75% | 3% | 38 |
9 | CA2 BINDING EF HAND | 48 | 100% | 1% | 17 |
10 | HEVIN | 48 | 100% | 1% | 17 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Diverse biological functions of the SPARC family of proteins | 2012 | 37 | 74 | 81% |
Stromal expression of SPARC in pancreatic adenocarcinoma | 2013 | 23 | 113 | 76% |
The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer | 2013 | 20 | 90 | 76% |
Modulation of matrix remodeling by SPARC in neoplastic progression | 2010 | 53 | 140 | 89% |
The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1 | 2013 | 16 | 115 | 82% |
Divergent Molecular Mechanisms Underlying the Pleiotropic Functions of Macrophage Inhibitory Cytokine-1 in Cancer | 2010 | 65 | 86 | 69% |
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer | 2006 | 87 | 27 | 89% |
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host | 2008 | 69 | 189 | 70% |
SPARC in cancer biology: Its role in cancer progression and potential for therapy | 2008 | 73 | 136 | 66% |
A prototypic matricellular protein in the tumor | 2008 | 64 | 107 | 70% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BARBARA JANE LEVY MOL NEUROONCOL | 15 | 71% | 0.9% | 12 |
2 | HOPE HEART PROGRAM | 12 | 29% | 2.5% | 34 |
3 | ST VINCENTS PL MED | 2 | 14% | 1.2% | 16 |
4 | MOL TRANSLAT CARDIOL | 2 | 24% | 0.7% | 9 |
5 | EICOSANOIDS BIOCHEM SECT | 2 | 67% | 0.1% | 2 |
6 | LIVER DIS PLA | 2 | 67% | 0.1% | 2 |
7 | MED BIOL STRUCT | 2 | 40% | 0.3% | 4 |
8 | HERMELIN BRAIN TUMOR | 2 | 12% | 1.1% | 15 |
9 | WILLIAM KAREN DAVIDSON CELL SIGNALING TUM | 1 | 30% | 0.2% | 3 |
10 | ALAN LIVINGSTONE CHAIR SURG ONCOL | 1 | 33% | 0.1% | 2 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000016068 | NOONAN SYNDROME//COSTELLO SYNDROME//THROMBOSPONDIN 1 |
2 | 0.0000015428 | PERIOSTIN//CONNECTIVE TISSUE GROWTH FACTOR//CCN2 |
3 | 0.0000015233 | OSTEOPONTIN//DENTAL PULP//AMELOGENIN |
4 | 0.0000008865 | TENASCIN C//TENASCIN//POLYSIALIC ACID |
5 | 0.0000007899 | UKRAIN//ANTITUMOR RESISTANCE//RE KAVETSKY EXPT PATHOL ONCOL RADIOBIOL |
6 | 0.0000007387 | OSTEOGENESIS IMPERFECTA//EHLERS DANLOS SYNDROME//EHLERS DANLOS SYNDROME TYPE IV |
7 | 0.0000007240 | ALPHAVBETA3 INTEGRIN//CILENGITIDE//DISCOIDIN DOMAIN RECEPTOR |
8 | 0.0000007083 | LAMININ//FIBRONECTIN//INVASION & METASTASIS |
9 | 0.0000007002 | HEREDITARY HEMORRHAGIC TELANGIECTASIA//ENDOGLIN//TGF BETA |
10 | 0.0000005939 | EGR 1//C FOS//CREM |